X-Chem, Inc., a provider of DNA-Encoded Library (DEL)-based discovery services, has acquired IntelliSyn, a Montreal-based drug discovery services company and its U.S.-based sister company, AviSyn. The acquisitions allow the Company to offer services for screening, hit validation and lead optimization on existing and new markets. Financial details were not disclosed.
 
Leveraging its DEX platform with libraries containing over 200 billion small molecules, X-Chem discovers new drug leads for biopharma clients. IntelliSyn’s services will complement X-Chem’s service offering as an additional downstream part of the drug discovery process, primarily in the field of medicinal chemistry, custom synthesis and scale-up process chemistry, supporting lead optimization through candidate identification.
 
“The acquisition of IntelliSyn and AviSyn will allow us to significantly extend our capabilities to support drug discovery. This will result in a more streamlined offering to our clients. Fast drug discovery is essential in today’s biopharma industry and our new integrated offering will support our clients by accelerating this phase of their drug discovery journey,” said Matt Clark, Chief Executive Officer at X-Chem.
 
IntelliSyn’s Founder and CEO Jeffrey Albert will join the X-Chem management team.